BioCentury
ARTICLE | Clinical News

BMS-955176: Phase IIa data

March 23, 2015 7:00 AM UTC

The double-blind, dose-escalation, international Phase IIa AI468002 trial in 60 patients with HIV-1 infection showed that once-daily oral BMS-955176 for 10 days met the primary endpoint of reducing pl...